CAMP · CAMP4 Therapeutics Corporation Common Stock
View on chartInsiders & Stakes
| Enavate Sciences GP, LLC | ▲ Buy | Open Market | 3,785,802 Shares held | 10/15/2024 | View profile |
| 5AM Partners VI, LLC 10% Owner | ▲ Buy | Open Market | 2,941,176 Shares held | 9/11/2025 | View profile |
| Andrew J. Schwab Director | ▼ Sell | Open Market | 2,033,270 Shares held | 8/27/2026 | View profile |
| Northpond Ventures II GP, LLC | ▲ Buy | Open Market | 763,636 Shares held | 10/15/2024 | View profile |
| AH Equity Partners Bio I, L.L.C. | ▲ Buy | Open Market | 545,454 Shares held | 10/15/2024 | View profile |
| Josh Mandel-Brehm Chief Executive Officer | ▲ Buy | Open Market | 284,968 Shares held | 8/3/2026 | View profile |
| Polaris Management Co. VII, L.L.C. | ▲ Buy | Open Market | 197,661 Shares held | 9/11/2025 | View profile |
| Amir Nashat Director | ▲ Buy | Open Market | 197,661 Shares held | 9/11/2025 | View profile |
| Richard A. Young Director | ▲ Buy | Open Market | 186,388 Shares held | 8/3/2026 | View profile |
| Holtzman Steven H Director | ▼ Sell | Other | 108,946 Shares held | 10/15/2024 | View profile |
| Yuri Maricich Chief Medical Officer | ▲ Buy | Open Market | 12,611 Shares held | 8/3/2026 | View profile |
| Kelly Gold Chief Financial Officer | ▲ Buy | Open Market | 10,000 Shares held | 8/31/2026 | View profile |
| Tardiff Daniel Chief Scientific Officer | ▼ Sell | Open Market | 0 Shares held | 8/19/2026 | View profile |
Transaction History
| Kelly Gold | ▲ Buy | Open Market | 10,000 | $40K | 8/31/2026 |
| Andrew J. Schwab | ▼ Sell | Open Market | 400,000 | $1.6M | 8/27/2026 |
| Andrew J. Schwab | ▼ Sell | Open Market | 10 | $45 | 8/24/2026 |
| Andrew J. Schwab | ▼ Sell | Open Market | 32,018 | $144K | 8/21/2026 |
| Andrew J. Schwab | ▼ Sell | Open Market | 114,700 | $521K | 8/20/2026 |
| Andrew J. Schwab | ▼ Sell | Open Market | 45,147 | $215K | 8/19/2026 |
| Tardiff Daniel | ▼ Sell | Open Market | 1,738 | $8K | 8/19/2026 |
| Richard A. Young | ▲ Buy | Open Market | 16,378 | $27K | 8/3/2026 |
| Yuri Maricich | ▲ Buy | Open Market | 6,551 | $11K | 8/3/2026 |
| Kelly Gold | ▲ Buy | Open Market | 6,551 | $11K | 8/3/2026 |
| Josh Mandel-Brehm | ▲ Buy | Open Market | 6,551 | $11K | 8/3/2026 |
| Andrew J. Schwab | ▲ Buy | Grant | 2,941,176 | $4.5M | 9/11/2025 |
| 5AM Partners VI, LLC | ▲ Buy | Open Market | 2,941,176 | $4.5M | 9/11/2025 |
| Polaris Management Co. VII, L.L.C. | ▲ Buy | Open Market | 1,221,721 | $1.9M | 9/11/2025 |
| Polaris Management Co. VII, L.L.C. | ▲ Buy | Open Market | 85,468 | $131K | 9/11/2025 |
| Amir Nashat | ▲ Buy | Open Market | 1,221,721 | $1.9M | 9/11/2025 |
| Amir Nashat | ▲ Buy | Open Market | 85,468 | $131K | 9/11/2025 |
| Yuri Maricich | ▲ Buy | Open Market | 6,060 | $10K | 9/11/2025 |
| Kelly Gold | ▲ Buy | Open Market | 6,060 | $10K | 9/11/2025 |
| Josh Mandel-Brehm | ▲ Buy | Open Market | 6,060 | $10K | 9/11/2025 |
| Richard A. Young | ▲ Buy | Open Market | 15,151 | $25K | 9/11/2025 |
| Northpond Ventures II GP, LLC | ▲ Buy | Open Market | 763,636 | $8.4M | 10/15/2024 |
| AH Equity Partners Bio I, L.L.C. | ▲ Buy | Open Market | 181,818 | $2.0M | 10/15/2024 |
| Andrew J. Schwab | ▼ Sell | Other | 302,770 | — | 10/15/2024 |
| 5AM Partners VI, LLC | ▼ Sell | Other | 302,770 | — | 10/15/2024 |
| 5AM Partners VI, LLC | ▲ Buy | Open Market | 909,090 | $10.0M | 10/15/2024 |
| Amir Nashat | ▼ Sell | Other | 24,745 | — | 10/15/2024 |
| AH Equity Partners Bio I, L.L.C. | ▲ Buy | Open Market | 545,454 | $6.0M | 10/15/2024 |
| Polaris Management Co. VII, L.L.C. | ▼ Sell | Other | 87,448 | — | 10/15/2024 |
| Polaris Management Co. VII, L.L.C. | ▼ Sell | Other | 353,718 | — | 10/15/2024 |
| Polaris Management Co. VII, L.L.C. | ▼ Sell | Other | 24,745 | — | 10/15/2024 |
| Polaris Management Co. VII, L.L.C. | ▲ Buy | Open Market | 909,090 | $10.0M | 10/15/2024 |
| 5AM Partners VI, LLC | ▼ Sell | Other | 1,716,055 | — | 10/15/2024 |
| Amir Nashat | ▲ Buy | Open Market | 909,090 | $10.0M | 10/15/2024 |
| Andrew J. Schwab | ▲ Buy | Open Market | 909,090 | $10.0M | 10/15/2024 |
| Holtzman Steven H | ▼ Sell | Other | 8,917 | — | 10/15/2024 |
| Richard A. Young | ▼ Sell | Other | 8,917 | — | 10/15/2024 |
| Amir Nashat | ▼ Sell | Other | 1,250,061 | — | 10/15/2024 |
| AH Equity Partners Bio I, L.L.C. | ▼ Sell | Other | 1,398,067 | — | 10/15/2024 |
| Josh Mandel-Brehm | ▼ Sell | Other | 605 | — | 10/15/2024 |
| Amir Nashat | ▼ Sell | Other | 87,448 | — | 10/15/2024 |
| Northpond Ventures II GP, LLC | ▼ Sell | Other | 471,415 | — | 10/15/2024 |
| Andrew J. Schwab | ▼ Sell | Other | 378,463 | — | 10/15/2024 |
| Enavate Sciences GP, LLC | ▼ Sell | Other | 2,422,166 | — | 10/15/2024 |
| Enavate Sciences GP, LLC | ▲ Buy | Open Market | 1,363,636 | $15.0M | 10/15/2024 |
| Polaris Management Co. VII, L.L.C. | ▼ Sell | Other | 1,250,061 | — | 10/15/2024 |
| Amir Nashat | ▼ Sell | Other | 353,718 | — | 10/15/2024 |
| Andrew J. Schwab | ▼ Sell | Other | 1,337,592 | — | 10/15/2024 |
| Northpond Ventures II GP, LLC | ▼ Sell | Other | 1,003,193 | — | 10/15/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial
CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial. CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.